Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNG1005 versus investigator's choice monotherapy chemotherapy in HER2-negative breast cancer brain metastases progressing after whole-brain radiotherapy
CTR20191654Phase 3Active
- Sponsor
- Xinnuokang Pharmaceutical Technology
- Start
- Dec 2022
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of paclitaxel trevatide in breast cancer, brain metastases, sponsored by Xinnuokang Pharmaceutical Technology. Started Dec 2022; status: active.
02
Drugs
paclitaxel trevatide
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on CTR20191654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191654.